Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

ACS sheet industry - Industry tailwinds to sustain - ICICI Securities

Posted On: 2020-10-25 23:46:36 (Time Zone: Arizona, USA)

We expect the asbestos cement sheet (ACS) industry to continue witnessing strong demand and pricing tailwinds in FY21 on the back of healthy rural demand. Being an oligopoly industry with the top-6 players accounting for ~80% of the industry size (Rs39bn, or 3.6mn-mtpa), we believe players with pan-India presence (HIL, Visaka, and Everest) are likely to witness strong earnings growth in FY21E. Besides healthy demand, pricing in the industry too held up in Q2 and Q3-TD (despite being seasonally weak quarters) and is expected to remain firm through the current fiscal. Our recent channel checks suggest: a) strong double-digit volume growth achieved by HIL in Q2FY21 while Visaka Industries and Everest Industries registered flat to low single-digit volume growth; and b) HIL's pricing is somewhat higher (QoQ) compared to its immediate peers.

- Higher rural income and steel sheet prices (alternative to ACS) to drive ACS industry growth over FY20-FY22E. Demand tailwind in ACS is likely to be driven by: 1) higher farm income through recent hike in MSP prices and back to back better monsoons; 2) migration of workers to rural areas in the wake of Covid breakout and higher allocation of Covid relief funds for rural India; 3) firm domestic steel prices (boosted by the adverse sentiment on China) making steel sheet prices relatively higher vs ACS. With these firm drivers likely to sustain in the near term, we expect ACS industry volumes to grow at 5-7% in FY21.

- ACS pricing remains unusually firm in an otherwise off-season period. Our channel checks across regions indicate ACS pricing is down by a mere 4-5% QoQ after rising by ~15% in Q1FY21. This limited price decline is due to sustained demand from rural India and firm pricing in steel-coated sheets. We thus expect Q2/Q3 realisations for top pan-India ACS players to show a high single-digit to low double-digit growth YoY in the current fiscal. If the strong demand sustains into Q4 (which marks the onset of seasonal demand) as well, we might witness ACS pricing to trend incrementally higher, which would drive strong realisations and profitability for the top ACS players in FY21.

- VSKI and HIL to be the biggest beneficiaries of industry tailwinds. We expect VSKI to sustain its strong volumes and profitability in its ACS segment in the current fiscal. HIL on the other hand is likely to stage a strong comeback after having faced muted demand and challenges w.r.t. sourcing of asbestos fibre in the base year (FY20). While Everest too would benefit from the industry tailwinds, it is likely to post lower earnings growth among its top peers (HIL and VSKI) due to higher volumes in the base year and aggressive pricing.

- Maintain BUY on VSKI with target price at Rs552. We expect VSKI to report overall revenue and PAT CAGRs of 6.3% and 27.2% respectively over FY20- FY22E. Higher profitability and stricter working capital discipline leading to sizeable paring of debt would aid VSKI in improving its RoCEs to 15%. We maintain BUY on the stock with an unchanged target price of Rs552, valuing it at 12x FY22E earnings.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Maintain ADD on Symphony - Domestic in line; RoW improving - HDFC Securities

Maintain ADD on Multi Commodity Exchange - Taking a pause; recovery awaited - HDFC Securities

Maintain ADD on DCB Bank - Provisioning cushion emerges ahead of expectations - HDFC Securities

Maintain BUY on Birla Corporation - Margin buoyancy continues - HDFC Securities

ADD on SRF - Returning to normalcy - HDFC Securities

HDFC Securities - Maintain BUY on UltraTech Cement - Solid show!

Ajanta Pharma (Initiating Coverage) - Gearing for the next leap - HDFC Securities

BUY on SBI Life Insurance - Growth returns - HDFC Securities

Kajaria Ceramics (Initiating Coverage) - Galloping ahead - HDFC Securities

UltraTech Q3 FY21 - YES Securities

HDFC Life Q3 FY21 - YES Securities

SBI Life - Q3 FY21 - YES Securities

Aavas Financiers Q3 FY21 - Conference Call Takeaways - YES Securities

Birla Corp Q3 FY21 - YES Securities

ADD on Reliance Industries - Sailed through the tough times! - HDFC Securities

Grasim Industries - Aspiring for strong no.2 position in paints - ICICI Securities

Kewal Kiran Clothing - Better execution with flat EBITDA YoY - ICICI Securities

Mphasis - DXC will continue to be key in the near term - ICICI Securities

HDFC Securities: Indian Chemical Sector (Sector Update) - Steering well through the pandemic!

UltraTech Cement - Earnings upgrade continues; ripe for rerating - ICICI Securities

Multi Commodity Exchange of India - Lower turnover impacted operating performance - Q3FY21 - ICICI Securities

SBI Life Insurance Company - Strong performance, attractive valuations (<2 FY23 P/EV) - ICICI Securities

Biocon Limited - Slow recovery in biosimilars - ICICI Securities

HDFC Life Insurance Company - Not only - but also - about protection - ICICI Securities

DCB Bank - Gradually approaching normalcy - ICICI Securities

Aurobindo Pharma - Approval for 3 products under PLI Scheme - ICICI Securities

Yes Bank - Aggravating asset quality fears outweigh operating performance turnaround - ICICI Securities

JSW Steel - Peak margins expected in Q4FY21 - ICICI Securities

Aavas Financiers - Quality intact; premium to sustain - ICICI Securities

Supreme Industries - Q3FY21 First Cut - ICICI Direct

Polycab India Ltd - Q3FY21 First Cut - ICICI Direct

DCB Bank - Q3FY21 First Cut - ICICI Direct

Q3FY21 Result update - Symphony Ltd. - ICICI Direct

Ultratech Cement - Q3FY21 First Cut - ICICI Direct

Oberoi Realty - Q3FY21 First Cut - ICICI Direct

HDFC Life Insurance - Q3FY21 First Cut - ICICI Direct

SRF Limited - Chemical biz's good performance may continue - ICICI Securities

Multi Commodity Exchange of India - Lower turnover impacted operating performance - ICICI Securities

Q3FY21 Company update - Zensar Technologies - ICICI Direct

JSW Steel - Q3FY21 First Cut - ICICI Direct

Q3FY21 Result update - Biocon Ltd - ICICI Direct

Symphony Ltd - Q3FY21 First Cut - ICICI Direct

Crompton Greaves Consumer Electricals - Q3FY21 First Cut - ICICI Direct

Q3FY21 Result update - Bajaj Finserv - ICICI Direct

Q3FY21 Result update - Bajaj Auto - ICICI Direct

Quant Pick - Hero MotoCorp - ICICI Direct

Company update - Cyient Ltd - Q3FY21 - ICICI Direct

Covid Recovery Pulse - Auto retail taper off in new year 2021 - ICICI Direct

Q3FY21 Result update - Asian Paints - ICICI Direct

Company update - Mphasis Ltd - Q3FY21 - ICICI Direct

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020